Research Portal

The BioNTech/ Pfizer vaccine effect

/

BioNTech (BNTX)

Our “new normal" came to a crashing halt on Monday after receiving the sobering news that a COVID-19 vaccine candidate had a 90% effective rate.

The vaccine candidate from the Pfizer/ BioNTech partnership has been a force to be reckoned with in the race to find a safe COVID-19 vaccine. Today we look at the smaller but no less effective company out of the vaccine partnership, namely BioNTech SE (BNTX). The Biotech company has truly exceeded expectations and grabbed the world’s attention.

Today is a great day for science and humanity. The first set of results from our phase 3 Covid-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent Covid-19,” - Dr Albert Bourla, the Pfizer chairman and chief executive.

Click to view BioNTech SE (BNTX) or Pfizer Inc (PFE) shares
on EasyEquities

New call-to-actionNew call-to-action

Fundamentals

BioNTech SE is a German-based biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases. The biotech company partnered with pharma giant Pfizer in April 2020 to accelerate the development of a COVID-19 vaccine.

The vaccine company reported third-quarter earnings on the 10th of November, which showed an increase of revenues of 135% year-over-year but missed on earnings per share. The company also reported a net loss of 210 million euros over the reporting period. 

BioNTech SE (BNTX) share overview:

  • Sector: Healthcare
  • Market Cap of $26.67 billion.
  • Price/Earnings (NTM): 23.5x
  • Price/Book: 24.7x
  • 52 Week Range low of $17.64 and $112.76 per share high.

Outlook – As the world starts to digest the fact that we could return to normal, the nasty realities begin to surface. The distribution of the vaccine could become a costly logistical nightmare seeing as the vaccine must be stored at an ultra-cool temperature of around -70 degrees Celsius and used within five days. 

Chart Life

The price action has been in a volatile but steady uptrend over the year, which has seen the share price gain 223.01% YTD. We might see a move lower as market participants take profits with a possible retracement lower to the $92.00 per share level a possibility.

Short interest as a percentage of outstanding shares on BioNTech SE (BNTX) is currently 0% which supports a positive outlook. The median analyst price expectations for BioNTech SE are $79.07 per share (red line).

BioNTechChart

Portfolio particulars

  • Portfolio Hold (Current)*
  • Portfolio Buy opportunity: above $77.00 per share **
  • WhatsTheBeef long term target price: $125.00 per share.

Click to view BioNTech SE (BNTX) or Pfizer Inc (PFE) shares
on EasyEquities

New call-to-actionNew call-to-action

Informed decisions

Vaccine stocks have been a hot topic over the year with stocks like Moderna Inc (MRNA), AstraZeneca PLC (AZN) and Pfizer Inc (PFE) leading the charge and also very attractive propositions. Looking forward, Pfizer/ BioNTech have reached an agreement to supply the European Union with 200 million doses of the vaccine, which could support the bottom line.

Much volatility is expected over the coming months taking into consideration the distribution hurdles facing vaccine companies, so EasyVestors should fasten those seatbelts when considering the investment.

New to investing

and want to know more about about Healthcare stocks?

Read: New Vaccine Stocks Land on Easy and Moderna (MRNA) vaccine to the rescue

Get these insights first & for free

 

Sources – EasyResearch, BioNTech SE, Reuters, SeekingAlpha, Koyfin, The Guardian, Wikipedia. 

Take note: stock data was taken on 28/11/2020 during the U.S market open. 

*Portfolio Hold (Current) refers to investors who already hold the stock within their portfolio before the U.S. market open.

**Portfolio Buy opportunity refers to Technical level crossed which might imply that the markets behavior would support the outlook and Close above refers to a share price close above a Technical Resistance level.

Follow Barry Dumas
@BEEF_FINMARKETS

Barry image

Barry is a market analyst with GT247, with a wealth of experience in the investment markets. Now in his tenth year in the markets, Barry "The Beef" Dumas brings a combination of technical analysis and fundamental insights to the table

Whats-the-beef-FB
 
Any opinions, news, research, reports, analyses, prices, or other information contained within this research is provided by Barry Dumas, Market Analyst at GT247 (Pty) Ltd t/a GT247.com (“GT247.com”) as general market commentary, and does not constitute investment advice for the purposes of the Financial Advisory and Intermediary Services Act, 2002. First World Trader (Pty) Ltd t/a EasyEquities (“EasyEquities”) and GT247.com do not warrant the correctness, accuracy, timeliness, reliability or completeness of any information received from third party data providers. You must rely solely upon your own judgment in all aspects of your investment and/or trading decisions and all investments and/or trades are made at your own risk. EasyEquities and GT247.com (including any of their employees) will not accept any liability for any direct or indirect loss or damage, including without limitation, any loss of profit, which may arise directly or indirectly from use of or reliance on the market commentary. The content contained within is subject to change at any time without notice.The value of a financial product can go down, as well as up, due to changes in the value of the underlying investments. An investor may not recoup the full amount invested. Past performance is not necessarily an indication of future performance. These products are not guaranteed. Examples and/or graphs are for illustrative purposes only.